Tyra Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Director and Officer Trading Arrangements
Rule 10b5-1 Trading Plans
From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended March 31, 2026, our officers and directors took the following actions with respect to such trading arrangements:
| Trading Arrangement | |||||
|---|---|---|---|---|---|
| Name and Title · Action · Date · Rule 10b5-1* · Non-Rule 10b5-1** · Total Shares Authorized to be Sold*** · Expiration Date | |||||
| Todd HarrisPresident, Chief Executive Officer and Director | Adoption | 3/6/2026 | X | 100,000 | 12/30/2027 |
| Alan FuhrmanChief Financial Officer | Adoption | 3/20/2026 | X | 100,000 | 12/30/2027 |
| Julia RuebVice President, Finance (principal accounting officer) | Adoption | 3/6/2026 | X | 56,975 | 10/20/2027 |
- Intended to satisfy the affirmative defense of Rule 10b5-1(c)
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)
***Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold is dependent on the satisfaction of certain conditions as set forth in the written plan and the satisfaction of applicable vesting conditions of equity awards.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.